FlandersBio offers an up-to-date life sciences database with detailed information about all FlandersBio members.
FlandersBio beschikt over een geüpdate life sciences databank met een gedetailleerd overzicht van alle FlandersBio-ledenbedrijven.
Multiplicom is specialized in the development, manufacturing and commercialization of innovative molecular genetic tests. These tests allow (i) to determine whether an individual has an increased genetic risk to develop a disease, (ii) early detection of congenital genetic defect, or (iii) to identify the most appropriate therapy for patients.
Multiplicom develops, manufactures and commercializes molecular diagnostic kits that enable personalized medicine. Founded in 2011 as a spin-off from the University of Antwerp and VIB, Multiplicom achieved end of 2012 its first CE/IVD-certification for the BRCA MASTR Dx assay for breast and ovarian cancer predisposition. It was the first company in Europe achieving a BRCA CE/IVD-certification and it continues to develop and market quality controlled MPS-based assays.
Therefore, it enables clinical laboratories to diagnose patients with a genetic disease or predisposition, steer cancer therapy, and identify congenital defects early in pregnancy. The Multiplicom N.V. site, located at Galileilaan 18 in Niel, Belgium, operates a Quality Management System to design, develop, manufacture and distribute CE-IVD products according to ISO 13485:2003 and EN ISO 13485:2012.
MASTR™ assays enable multiplex PCR amplification of all required coding sequences of the genes of interest in a limited number of PCR reactions. Further downstream pooling of DNA amplicons and barcoding individual samples of the MASTR™ assays with contemporary massive parallel sequencing (MPS) technologies, allows simple, high throughput and cost-effective sequencing for both research and diagnostic purposes.